Laila Samady-Mustad

With a Ph.D. in Molecular Pathology and Immunology from University College London (UCL), Laila is a research scientist and strategic advisor with more than 20 years of experience in the pharmaceutical, medical, and biotechnology industry in the UK, US, and France. Her expertise is in medical affairs, partnership, business development, and capital raising strategies. She is currently a strategic advisor to a number of health-related companies in digital health and medical diagnostics. Her work at UCL led to the development of patents and a spin-out company, BioVex which was acquired by Amgen in 2011 for $1B. While at Boehringer Ingelheim, she served in increasingly senior roles initially in cardiovascular medical affairs leading to a global strategic role in oncology medical affairs and Global Trial Alliance Manager. Prior to her Ph.D., she obtained a BSc in Biochemistry at Trinity College, Hartford, CT, and MSc in Molecular and Cell Biology from Institut Pasteur, Paris.